BROMOCRIPTINE NONCLINICAL SUMMARY PDF

Non-clinical Aspects. Outline. • Overview of Legal and Regulatory requirements. • Structure of the dossier (CTD). • Overview of Scientific Non-clinical Guidelines. These highlights do not include all the information needed to use CYCLOSET safely and effectively. See full prescribing information for CYCLOSET. CYCLOSET. Also, in clinical studies bromocriptine did not influence follicle stimulating .. For a recent overview of possible strategies to develop drug.

Author: Negar Tugal
Country: Peru
Language: English (Spanish)
Genre: Marketing
Published (Last): 18 November 2013
Pages: 431
PDF File Size: 16.3 Mb
ePub File Size: 13.68 Mb
ISBN: 524-8-40091-623-5
Downloads: 36255
Price: Free* [*Free Regsitration Required]
Uploader: Tuzragore

Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. These exposure differences between animals and humans were considered sufficient by the European Medicines Agency EMA to conclude that the APF is of no concern for the intended clinical use A strategy for risk nonclinicxl of drug-induced phospholipidosis. Peroxisome proliferation under exposure to these compounds is generally most marked in rats and mice, less in hamsters, and only slightly, if at all, in guinea pigs, monkeys, and humans.

Amantadine Budipine Methylxanthines e. Monitoring for PLD in clinical studies is possible e. Vasodilation could also have played a major role in the lesions described here.

It is rarely possible to establish the MoA and our understanding of these types of APF is generally too limited to allow extrapolation of such animal data to humans. Often and despite further investigations the MoA and therefore the relevance of a vascular APF for man are not known.

Read Also:  AMORES ALTAMENTE PELIGROSOS WALTER RISO DESCARGAR GRATIS DOWNLOAD

Kinase activity profiling as powerful tool in functional studies.

Bromocriptine – Wikipedia

If MEK is inhibited, vitamin D is no longer inactivated Are we there yet? Absence of oocytes means permanent female infertility, similar smumary menopause initiated in humans by exhaustion of available oocytes. Evaluation on carcinogenicity of chemicals using transgenic mice.

The additional data also suggested that the hyperplastic response was due to local tegaserod exposure. Developing drugs and therapeutic biologics for treatment and prevention. Toxic and drug-induced myopathies. Summarj some of the above factors and events may nobclinical play a role for the induction of sarcomas in rats, a specific MoA has so far not been proven for this species.

Oral anti-diabetic drugsinsulins and insulin analogsand other drugs used in diabetes A The uterine APF in rats is without relevance for women and considered to be an exaggerated pharmacodynamic effect of bromocriptine specific for aging female rats 23 The test may be used to generate additional data, but the molecular basis of cell transformation is not well understood.

Species-related differences regarding the function of the retina limit the predictive value of bromocruptine tools 19 Jacobson-Kram D, Jacobs A.

Inotropic and chronotropic effects lead to a work overload with underperfusion of areas supplied by end arteries and shortening of the diastolic period when blood perfusion takes place. The carcinogenic alert noonclinical with an increasing number of positive parameters as listed below:. Clinical and experimental neurology.

Among the various tests the sister chromatid exchange assay SCE had the largest percentage of positives The MoA of drug candidates with potential genotoxicity and teratogenicity can often not be established. Lesions were also reported in the monkey urothelium, but the pathology working group of the HESI PPAR Agonist Project Committee ascertained that the suspect findings were normal in the monkey urothelium and epithelial hyperplasia was absent Cardiotoxicity induced by tyrosine kinase inhibitors.

Read Also:  TL431K PDF

The acceptable daily intake of genotoxic substances varies between approximately 1.

Bromocriptine

This second part of the review concentrates on a more detailed discussion of selected APFs of drugs nonclinlcal far as possible with reference to their MoA and regarding their relevance for man. Furthermore only minor mineralization is seen in dogs and monkeys.

Transgenic mouse models are not accepted. PLD inducers are often effective drugs, as their lipophilicity facilitates permeability into various tissues. For functional CNS toxicity see first part of this review. Toxicogenomics in risk assessment: Alternative noonclinical models for carcinogenicity assessment: Pregnancy and the drug dilemma. The elucidation of the MoA of dopaminergic drug candidates in laboratory animals also illustrates the importance of carefully planning additional experiments, as an explanation for the uterine findings is only possible taking into account the age-specific nonclinifal hormone climate in aging rats.